Fintel reports that on October 26, 2023, Mizuho maintained coverage of Alkermes (NASDAQ:ALKS) with a Buy recommendation.
Analyst Price Forecast Suggests 51.36% Upside
As of October 5, 2023, the average one-year price target for Alkermes is 37.40. The forecasts range from a low of 30.30 to a high of $51.45. The average price target represents an increase of 51.36% from its latest reported closing price of 24.71.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Alkermes is 1,179MM, a decrease of 25.88%. The projected annual non-GAAP EPS is 0.36.
What is the Fund Sentiment?
There are 667 funds or institutions reporting positions in Alkermes. This is an increase of 26 owner(s) or 4.06% in the last quarter. Average portfolio weight of all funds dedicated to ALKS is 0.38%, a decrease of 4.04%. Total shares owned by institutions decreased in the last three months by 0.38% to 179,061K shares. 
The put/call ratio of ALKS is 0.32, indicating a bullish outlook.
What are Other Shareholders Doing?
Sarissa Capital Management holds 14,040K shares representing 8.43% ownership of the company. In it's prior filing, the firm reported owning 8,965K shares, representing an increase of 36.15%. The firm increased its portfolio allocation in ALKS by 35.35% over the last quarter.
Wellington Management Group Llp holds 7,691K shares representing 4.62% ownership of the company. In it's prior filing, the firm reported owning 6,710K shares, representing an increase of 12.75%. The firm increased its portfolio allocation in ALKS by 21.44% over the last quarter.
Hardman Johnston Global Advisors holds 5,608K shares representing 3.37% ownership of the company. In it's prior filing, the firm reported owning 5,763K shares, representing a decrease of 2.75%. The firm decreased its portfolio allocation in ALKS by 9.87% over the last quarter.
Renaissance Technologies holds 5,166K shares representing 3.10% ownership of the company. In it's prior filing, the firm reported owning 4,939K shares, representing an increase of 4.40%. The firm increased its portfolio allocation in ALKS by 26.13% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 5,150K shares representing 3.09% ownership of the company. In it's prior filing, the firm reported owning 5,094K shares, representing an increase of 1.10%. The firm increased its portfolio allocation in ALKS by 3.58% over the last quarter.
Alkermes Background Information
(This description is provided by the company.)
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
